OncoMatch/Clinical Trials/NCT06048250
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Is NCT06048250 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Mezigdomide for multiple myeloma.
Treatment: Mezigdomide — This phase I trial studies the safety, side effects, best dose and effectiveness of mezigdomide (CC-92480) when given after idecabtagene vicleucel (Abecma chimeric antigen receptor \[CAR\] T-cell therapy) in patients with multiple myeloma that has come back after a period of improvement (relapsed). CC-92480 works by binding to a protein called CRBN that triggers the breakdown of proteins: Ikaros and Aiolos, leading to cell death in multiple myeloma cells. Giving mezigdomide after Abecma CAR T cell therapy may extending the amount of time that the CAR T cells persist in the body in patients with relapsed multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunomodulatory agent
Subject must have received at least 4 prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody
Must have received: proteasome inhibitor
Subject must have received at least 4 prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody
Must have received: anti-CD38 antibody
Subject must have received at least 4 prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody
Must have received: CAR-T cell therapy (idecabtagene vicleucel)
Receipt of commercially available idecabtagene vicleucel (Abecma) according to FDA approved US Prescribing Information
Cannot have received: mezigdomide (mezigdomide, CC-92480)
Prior exposure to mezigdomide (CC-92480)
Lab requirements
Blood counts
ANC >= 1,500/mm^3 without the use of filgrastim in the previous 3 days; Platelets >= 75,000/mm^3 without platelet transfusion in the previous 3 days
Kidney function
Creatinine clearance of >= 50 mL/min per 24 hour urine test or the Cockcroft-Gault formula
Liver function
Total bilirubin <= 1.5 X ULN (unless has known Gilbert's disease); AST <= 3 x ULN; ALT <= 3 x ULN; Alkaline phosphatase <= 5 x ULN
ANC >= 1,500/mm^3 without the use of filgrastim in the previous 3 days; Platelets >= 75,000/mm^3 without platelet transfusion in the previous 3 days; Total bilirubin <= 1.5 X ULN (unless has known Gilbert's disease); AST <= 3 x ULN; ALT <= 3 x ULN; Alkaline phosphatase <= 5 x ULN; Creatinine clearance of >= 50 mL/min per 24 hour urine test or the Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06048250 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior mezigdomide disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages